Novel PET probes specific for deoxycytidine kinase

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1092-1098

  Shu, Chengyi J ^a   Campbell, Dean O ^b,c   Lee, Jason T ^b,c   Tran, Andrew Q ^b,c   Wengrod, Jordan C ^b,c,d   Witte, Owen N ^b,c   Phelps, Michael E ^b,c   Satyamurthy, Nagichettiar ^b,c   Czernin, Johannes ^b,c   Radu, Caius G ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Cytidine deaminase (CDA); Deoxycytidine kinase (dCK); Deoxyribonucleoside salvage; Malignant lymphoproliferation; PET probes

Indexed keywords

DEOXYCYTIDINE KINASE; FLUORODEOXYGLUCOSE F 18; RADIOISOTOPE; ADENINE NUCLEOTIDE; ARABINONUCLEOSIDE; CLOFARABINE; DIAGNOSTIC AGENT; LACTATE DEHYDROGENASE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHEMICAL STRUCTURE; DEAMINATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTILLATION PROBE; ANIMAL; BINDING COMPETITION; BIOTRANSFORMATION; CELL LINE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENZYME SPECIFICITY; LYMPHOPROLIFERATIVE DISEASE; METABOLISM; PHOSPHORYLATION; SCINTISCANNING; SYNTHESIS; WHOLE BODY IMAGING;

ADENINE NUCLEOTIDES; ANIMALS; ARABINONUCLEOSIDES; BINDING, COMPETITIVE; BIOTRANSFORMATION; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE KINASE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOPROLIFERATIVE DISORDERS; MICE; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE BODY IMAGING;

EID: 77954969861     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073361     Document Type: Article

References (31)

1. Staub M, Eriksson S. The role of deoxycytidine kinase in DNA synthesis and nucleoside analog synthesis. In: Peters GJ, ed. Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy. Totowa, NJ: Humana Press Inc.; 2006:29-52.
2. Eriksson S, Arner E, Spasokoukotskaja T, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul. 1994;34:13-25.
3. Durham JP, Ives DH. Deoxycytidine Kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-β-D-arabinofuranosylcytosine phosphorylation. Mol Pharmacol. 1969;5:358-375.
4. 18F]-labeled 2'-deoxycytidine analog. Nat Med. 2008;14:783-788.
5. Toy G, Austin WR, Liao H-I, et al. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci USA. 2010;107:5551-5556.
6. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008;27:6522-6537.
7. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-426.
8. Sabini E, Hazra S, Ort S, Konrad M, Lavie A. Structural basis for substrate promiscuity of dCK. J Mol Biol. 2008;378:607-621.
9. Lamba JK, Crews K, Pounds S, et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007;323:935-945.
10. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875-890.
11. Radu CG, Witte ON, Nair-Gill ED, Satyamurthy N, Shu CJ, Czernin J, inventors; The Regents of the University of California, assignee. Positron emission tomography probes for imaging immune activation and selected cancers. US patent 2009/0105184. April 23, 2009.
12. Laing RE, Walter MA, Campbell DO, et al. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci USA. 2009;106:2847-2852.
13. Ho DH. Distribution of kinase and deaminase of 1-β-D- arabinofuranosylcytosine in tissues of man and mouse. Cancer Res. 1973;33:2816-2820.
14. Richards DA, Sherwood RA, Ndebele D, Rocks BF. Determination of plasma cytidine deaminase activity by HPLC. Biomed Chromatogr. 1987;2:148-151.
15. Krenitsky TA, Tuttle JV, Koszalka GW, et al. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J Biol Chem. 1976;251:4055-4061.
16. Sun H, Collins JM, Mangner TJ, Muzik O, Shields AF. Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies. Cancer Chemother Pharmacol. 2006;57:343-348.
17. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA, III, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5:855-863.
18. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res. 1999;5:2438-2444.
19. Fanucchi MP, Watanabe KA, Fox JJ, Chou TC. Kinetics and substrate specificity of human and canine cytidine deaminase. Biochem Pharmacol. 1986;35:1199-1201.
20. Maury G. The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy? Antivir Chem Chemother. 2000;11:165-189.
21. Sabini E, Hazra S, Konrad M, Lavie A. Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007;50:3004-3014.
22. Kiianitsa K, Solinger JA, Heyer WD. NADH-coupled microplate photometric assay for kinetic studies of ATP-hydrolyzing enzymes with low and high specific activities. Anal Biochem. 2003;321:266-271.
23. Johansson M, van Rompay AR, Degreve B, Balzarini J, Karlsson A. Cloning and characterization of the multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster. J Biol Chem. 1999;274:23814-23819.
24. Shewach DS, Liotta DC, Schinazi RF. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol. 1993;45:1540-1543.
25. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3'-deoxy-3'-[F-18] fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4:83-89.
26. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
27. Morse HC, 3rd, Davidson WF, Yetter RA, Murphy ED, Roths JB, Coffman RL. Abnormalities induced by the mutant gene lpr: expansion of a unique lymphocyte subset. J Immunol. 1982;129:2612-2615.
28. Kelley VE, Roths JB. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol. 1985;37:220-229.
29. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
30. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49(suppl 2):64S-80S.
31. Dobrovolsky VN, Bucci T, Heflich RH, Desjardins J, Richardson FC. Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Mol Genet Metab. 2003;78:1-10.